A real-life experience of dermatological manifestations associated with direct-acting antivirals for chronic hepatitis C virus infection

A Study of Hepatocellular Carcinoma in Chronic Hepatitis C Patients Received Direct Acting Antiviral Drugs

Study of Frequency of Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy in Hepatitis C Virus Patients

Dermatological Manifestations of Pegylated Interferon alfa2a and Ribavirin Combination Therapy in Chronic HCV Patients

The occurrence of thrombotic thrombocytopenic purpura during treatment of HCV with direct-acting antiviral agents

Frequency of Hepatocellular Carcinoma in HCV Patients Treated with Direct-Acting Antiviral Drugs

Incidence of hepatocellular carcinoma one year after direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis; A multicenter s

Hepatocellular Carcinoma in Hepatitis C Virus Cirrhosis After Treatment with Direct Acting Antiviral Therapy

Long-term Follow-up of Chronic Hepatitis C Patients Treated by Direct- Acting Antivirals

Direct Acting Antivirals Impact on Biochemical, Immunological and Hematological Responses in HCV Infected Patients